Patent №
US 12,465,686
Granted
2025-11-11
Filed 2022
Owner
Beta Bionics, Inc.
Lab
—
AI components
0
Assignment
None on record
Dataset
AIPD
Application
17882469
Automated glucose level control system that provide therapy to a subject, such as glucose control, are disclosed. The system generates dose control signals using control algorithms configured to autonomously determine doses of insulin to be infused into a subject. When the system determines that an initial dose control signal does not indicate health-appropriate therapy, the system can modify a manual therapy instruction and transmit an emergency dose control signal to the medicament pump. Disclosed systems and devices can track insulin therapy administered to the subject over a tracking period, including storing an indication of the autonomously determined doses of insulin delivered to the subject. The system can generate a backup therapy protocol with insulin therapy instructions based at least in part on the insulin therapy administered to the subject over the tracking period.
Ownership
Beta Bionics, Inc.